[Bringing the antiviral therapy home for chronic hepatitis B patients: host immunity influences the efficacy and disease prognosis].
Wang
Fu-Sheng
FS
Research Center for Biological Therapy, Beijing 302 Hospital, China. fswang@public.bta.net.cn
Zhang
Ji-Yuan
JY
D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D006801:Humans; D007167:Immunotherapy; D011379:Prognosis; D014779:Virus Replication / Q000187:drug effects*
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens